Robin L. Smith

Insider Reports History

Entity
Individual
Location
C/O Phase III Medical, Inc., 330 South Service Road, Suite 120, Melville, NY
Signature
/s/ Kyle Fletcher, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Robin L. Smith:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Sorrento Therapeutics, Inc. Director Common Stock 235K $189K $0.80 Sep 3, 2021 Direct
Celularity Inc Director Class A Common Stock 236K $58.8K $0.25 Jun 14, 2023 Direct
Celularity Inc Director Stock Option (Right to Buy) 278K Jun 14, 2023 Direct
Sorrento Therapeutics, Inc. Director Stock Options 0 Sep 3, 2021 Direct

Insider Reports Filed by Robin L. Smith

Symbol Company Period Transactions Value $ Form Type Date Filed Role
CELU Celularity Inc Jun 14, 2023 2 $0 4 Jun 16, 2023 Director
CELU Celularity Inc Aug 16, 2022 2 $0 4 Aug 18, 2022 Director
CELU Celularity Inc Jul 13, 2022 2 $0 4 Jul 15, 2022 Director
WAVS Western Acquisition Ventures Corp. Jan 11, 2022 0 $0 3 Jan 11, 2022 Director
CELU Celularity Inc Sep 9, 2021 1 $0 4 Sep 13, 2021 Director
SRNEQ Sorrento Therapeutics, Inc. Sep 3, 2021 4 $785K 4 Sep 3, 2021 Director
SRNEQ Sorrento Therapeutics, Inc. Aug 30, 2021 1 $0 4 Aug 30, 2021 Director
CELU Celularity Inc Jul 16, 2021 2 $0 4 Jul 20, 2021 Director
CELU GX Acquisition Corp. Jul 16, 2021 0 $0 3 Jul 16, 2021 Director